Oleoyl-L-carnitine, a long-chain acylcarnitine, acts as a selective inhibitor of glycine transporter 2 (GlyT2; IC50 = 340 nM) while demonstrating significantly lesser affinity for GlyT1 (IC50 = >10,000 nM). Elevated plasma levels of this compound have been observed in patients suffering from chronic kidney disease or end-stage renal disease undergoing initial hemodialysis, correlating with an increased risk of cardiovascular mortality.